

Supplementary Information for

Keratoconus-susceptibility genes identification by corneal thickness genome-wide association study and artificial intelligence IBM Watson

***Corresponding Author:**

Masahiro Miyake, MD, PhD, MPH

Department of Ophthalmology and Visual Sciences

Kyoto University Graduate School of Medicine

54 Shogoin, Kawahara, Sakyo, Kyoto 606-8507, Japan

Tel.: +81-75-751-3248

Fax: +81-75-752-0933

This PDF file includes:

Supplementary Figures 1


Supplementary Table 1 to 4

Supplementary Note

SI References

Supplementary Figure 1: Quantile–quantile (QQ) plot from the discovery stage.

A QQ plot of the associations between all analyzed SNPs and myopic maculopathy in the discovery stage. Each blue dot represents an observed P -value (represented on a $-\log_{10}$ scale) versus the corresponding expected P -value before genomic control, whereas each red dot represents the observed P -value versus the corresponding expected P -value after genomic control. The black line corresponds to the null distribution.



Supplementary Table 1. Description of the Nagahama cohort for our two-stage genome-wide association study (GWAS) of corneal thickness (CCT)

Stage	N	Female (%)	Age (years)	CCT (μm)	AL (mm)
Discovery	3,584	2,445 (68.2)	56.4 \pm 13.0	544 \pm 28	24.08 \pm 1.34
Replication	2,942	2,000 (68.0)	58.6 \pm 12.2	545 \pm 28	23.98 \pm 1.33

AL, average axial length in both eyes. The data shown are expressed as the mean \pm standard deviation.

Supplementary Table 2. List of candidate genes included in the Watson predictive analysis

Gene	Comment	Included in Watson analysis?
<i>LOC100132571</i>	No literature	No
<i>LOC101926919</i>	No literature	No
<i>LOC101927874</i>	No literature	No
<i>LOC285419</i>	No literature	No
<i>BC045810</i>	No literature	No
<i>LOC100506700</i>	No literature	No
<i>LOC100419872</i>	No literature	No
<i>LOC400456</i>	No literature	No
<i>STON2</i>	Teacher gene	No
<i>FNDC3B</i>	Teacher gene	No
<i>FOXO1</i>	Teacher gene	No
<i>NRXN1</i>		Yes
<i>SPTBN1</i>		Yes
<i>MEIS1</i>		Yes
<i>GLS</i>		Yes
<i>ARNT</i>		Yes
<i>OSBPL10</i>		Yes
<i>SLC7A11</i>		Yes
<i>CPLX2</i>		Yes
<i>SUPT3H</i>		Yes
<i>CSMD1</i>		Yes
<i>ADRA1A</i>		Yes
<i>FAM49B</i>		Yes
<i>C10orf68</i>		Yes
<i>PLEKHS1</i>		Yes
<i>ADAM12</i>		Yes
<i>MGMT</i>		Yes
<i>MTCH2</i>		Yes
<i>PKNOX2</i>		Yes
<i>ADAMTS15</i>		Yes
<i>KCNA6</i>		Yes
<i>SLCO1B1</i>		Yes
<i>CIT</i>		Yes
<i>DOCK9</i>		Yes

<i>SLC24A4</i>	Yes
<i>SMAD3</i>	Yes
<i>SEMA4B</i>	Yes
<i>CIB1</i>	Yes
<i>TTC23</i>	Yes
<i>ADAMTS17</i>	Yes
<i>CERS3</i>	Yes
<i>WWOX</i>	Yes
<i>CDH13</i>	Yes
<i>SMG6</i>	Yes
<i>GAS7</i>	Yes
<i>SLC47A2</i>	Yes
<i>ALDH3A1</i>	Yes
<i>DCAKD</i>	Yes
<i>NMT1</i>	Yes
<i>TBX4</i>	Yes
<i>ALPK2</i>	Yes
<i>ARHGEF1</i>	Yes
<i>MKKS</i>	Yes

Supplementary Table 3. Similarity scores of 42 genes analysed using Watson for Drug Discovery (WDD)

Gene	Similarity score	Rank
<i>SMAD3</i>	0.062	1
<i>CDH13</i>	0.05	2
<i>GAS7</i>	0.049	3
<i>CIB1</i>	0.046	4
<i>MEIS1</i>	0.046	5
<i>ARNT</i>	0.043	6
<i>DOCK9</i>	0.04	7
<i>CSMD1</i>	0.038	8
<i>WWOX</i>	0.037	9
<i>NRXN1</i>	0.036	10
<i>SPTBN1</i>	0.036	11
<i>ADAM12</i>	0.035	12
<i>PLEKHS1</i>	0.034	13
<i>ADAMTS17</i>	0.027	14
<i>ADAMTS15</i>	0.027	15
<i>CPLX2</i>	0.024	16
<i>SEMA4B</i>	0.024	17
<i>ARHGEF1</i>	0.024	18
<i>MGMT</i>	0.024	19
<i>TTC23</i>	0.024	20
<i>OSBPL10</i>	0.023	21
<i>MTCH2</i>	0.023	22
<i>SUPT3H</i>	0.023	23
<i>MKKS</i>	0.023	24
<i>CERS3</i>	0.023	25
<i>ALDH3A1</i>	0.023	26
<i>SMG6</i>	0.022	27
<i>SLC7A11</i>	0.022	28
<i>GLS</i>	0.022	29
<i>NMT1</i>	0.022	30
<i>ADRA1A</i>	0.022	31

<i>DCAKD</i>	0.015	32
<i>PKNOX2</i>	0.013	33
<i>FAM49B</i>	0.013	34
<i>SLC24A4</i>	0.013	35
<i>ALPK2</i>	0.013	36
<i>SLC47A2</i>	0.013	37
<i>SLCO1B1</i>	0.012	38
<i>CIT</i>	0.004	39
<i>TBX4</i>	0.004	40
<i>KCNA6</i>	0.003	41
<i>C10ORF68</i>	0.003	42

Supplementary Table 4. Description of the Asian cohorts included in CCT meta analysis

Study	N	Female (%)	Age (years)	CCT (μm)	AL (mm)	Genotyping platform	Imputation	CCT-measurement method
Nagahama (discovery)	3,584	2,445 (68.2)	56.4 \pm 13.0	544 \pm 28	24.08 \pm 1.34	HumanHap610 Quad, HumanOmni2.5, CoreExome24, and HumanExome	MACH	TX-20P
Nagahama (replication)	2,942	2,000 (68.0)	58.6 \pm 12.2	545 \pm 28	23.98 \pm 1.33	TaqMan SNP genotyping assay	-	TX-20P
SiMES	2,510	1,244 (49.6)	59.6 \pm 11.0	540 \pm 33	-	HumanHap610 Quad	Minimac	Ultrasonic pachymetry
SCES	1,861	952 (51.2)	58.5 \pm 9.5	553 \pm 33	-	HumanHap610 Quad	Minimac	Ultrasonic pachymetry
SCES2	608	312 (51.3)	60.4 \pm 9.5	552 \pm 33	-	OmniExpress	Minimac	Ultrasonic pachymetry
SINDI	2,508	1,288 (51.4)	58.0 \pm 10.0	540 \pm 33	-	HumanHap610 Quad	Minimac	Ultrasonic pachymetry

The data shown are expressed as the mean \pm standard deviation.

Supplementary Notes

SiMES, SCES, and SINDI cohorts

Each cohort was comprised of a population-based, cross-sectional group of Malay, Chinese, and Indian adults, aged 40 – 80 years. The details of the cohort designs were described previously.¹⁻³ Briefly, an age-stratified random sampling of adults residing in Singapore, aged 40 – 80 years, was drawn from a computer-generated random list of names provided by the Ministry of Home Affairs, for each cohort. A final sampling frame of residents was derived from this list using an age-stratified random sampling strategy.

BeadChip DNA arrays, namely the OmniExpress chip and HumanHap610 Quad chip (Illumina, San Diego, CA, US), were used to determine the sample genotypes. The *STON2* rs2371597 genotypes were determined by genotype imputation. Imputation was performed using Minimac software (<https://genome.sph.umich.edu/wiki/Minimac>).

Keratoconus cohort

Japanese patients with keratoconus (n = 179) were recruited from the Yokohama City University Hospital. All procedures adhered to the tenets of the Declaration of Helsinki. The Institutional Review Board and the Ethics Committee of each participating institute approved the study protocols. All patients were fully informed of the purpose and procedures of the study, and written consent was received from each patient prior to their participation in the study. All patients underwent a comprehensive ophthalmic

examination, including corneal topography and visual acuity evaluation. Keratoconus was diagnosed as an eye with corneal thinning, corneal scarring, or significant visual acuity loss.

A BeadChip DNA array, namely the Human OmniExpress chip (Illumina), was used to determine the genotypes of patients with keratoconus. The genotypes of *CPLX2* rs4242187, *ADAM12* rs11244890, *SMAD3* rs12913547, and *CDH13* rs1035533 were directly determined using the chip, and the genotypes of *STON2* rs2371597, *NRXN1* rs13382330, *CSMD1* rs143428993, and *WWOX* rs6564538 were determined by genotype imputation with the 1000 Genomes dataset (phase 3, v5 release) as a reference panel.

Japanese control cohorts

Control subjects from Yokohama City University

Normal Japanese subjects (N = 1018) were recruited from the Yokohama City University Hospital. A BeadChip DNA array, namely the Human OmniExpress chip (Illumina) was used to determine the genotypes of patients with keratoconus. Samples with a call rate of <97% were excluded. SNPs were excluded, based on the following quality-control criteria: a call rate of <98%, significantly different rates of missing data between patients and control subjects ($P < 1.0 \times 10^{-6}$), an overall minor allele frequency of <1%, and a significant deviation from Hardy–Weinberg equilibrium (HWE) in the control subjects ($P < 1.0 \times 10^{-5}$). Additionally, cryptic relatedness between samples was estimated based on identity by descent; closely related samples with a π -hat > 0.1875 were eliminated. The Michigan imputation server (<https://imputationserver.sph.umich.edu/index.html#!pages/home>) was used, with the

1000 Genomes dataset (phase3 v5 release) serving as a reference panel. All imputed SNPs were filtered using the following quality-control parameters: a MAF of >0.01 and a squared correlation between imputed and true genotypes (r^2) of >0.7 . The genotypes of *CPLX2* rs4242187, *ADAM12* rs7089454, *SMAD3* rs12913547, and *CDH13* rs1035533 were directly determined using the chip, and the genotypes of *STON2* rs2371597, *NRXNI* rs13382330, *CSMD1* rs143428993, and *WWOX* rs6564538 were determined by genotype imputation with the 1000 Genomes dataset (phase 3, v5 release) as a reference panel.

Nagahama cohort

A detailed description of the Nagahama cohort is provided in the Online Methods section.

ToMMo database

The Integrative Japanese Genome Variation Database (version 3.5KJPN, <https://ijgvd.megabank.tohoku.ac.jp/>) provides genomic reference panels obtained from 3,554 normal Japanese subjects. The details of the cohort were described previously.⁴⁻⁶ Briefly, samples were recruited from the Tohoku Medical Megabank Organization, Iwate Medical Megabank Organization, Nagahama Prospective Cohort for Comprehensive Human Bioscience, and National Hospital Organization Nagasaki Medical Center. The whole-genome sequences of all DNA samples were obtained using an Illumina HiSeq 2500 instrument. The resulting dataset contains the allele-frequency data of 37,067,715 reliable autosomal SNVs detected by whole-genome sequencing of 3,552 Japanese individuals (3.5KJPN, released September 28, 2017). We used a dataset

comprised of 7,931,579 SNVs with allele frequencies of $\geq 1\%$ in the Japanese population.

References

1. Cornes, B. K. *et al.* Identification of four novel variants that influence central corneal thickness in multi-ethnic Asian populations. *Hum. Mol. Genet.* **21**, 437–445 (2012).
2. Lavanya, R. *et al.* Methodology of the Singapore Indian Chinese Cohort (SICC) eye study: quantifying ethnic variations in the epidemiology of eye diseases in Asians. *Ophthalmic Epidemiol.* **16**, 325–336 (2009).
3. Foong, A. W. P. *et al.* Rationale and methodology for a population-based study of eye diseases in Malay people: the Singapore Malay Eye Study (SiMES). *Ophthalmic Epidemiol.* **14**, 25–35 (2007).
4. Kuriyama, S. *et al.* The Tohoku Medical Megabank Project: design and mission. *J. Epidemiol.* **26**, 493–511 (2016).
5. Nagasaki, M. *et al.* Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. *Nat. Commun.* **6**, 8018 (2015).
6. Yamaguchi-Kabata, Y. *et al.* iJGVD: an integrative Japanese genome variation database based on whole-genome sequencing. *Hum. Genome Var.* **2**, 15050

(2015).